Full Press Release Details
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences.
Jefferies Virtual Healthcare Conference
Format: Presentation and 1x1s
Tuesday, June 1, 2021
Goldman Sachs 42nd Annual Healthcare Conference
Format: Fireside Chat and 1x1s
Tuesday, June 8, 2021
A live webcast of both presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.
Fanny Cavalié, Foghorn Therapeutics
Gregory Kelley, Ogilvy
Investor Relations Contact:
Allan Reine, Foghorn Therapeutics
Hans Vitzthum, LifeSci Advisors